Evidence map›Paper›PMID 40045559›Full record

SynthesisFuture oncology (London, England)2025

Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC.

Elena Castro, Di Wang, Sarah Walsh, Samantha Craigie, Anja Haltner, Jonathan Nazari, Alexander Niyazov, Imtiaz A Samjoo

Abstract readSystematic ReviewComparative StudyMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elena CastroDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-3691-6454
Di WangValue & Evidence, EVERSANA™, Burlington, ON, Canada.
Sarah WalshValue & Evidence, EVERSANA™, Burlington, ON, Canada.
Samantha CraigieValue & Evidence, EVERSANA™, Burlington, ON, Canada.
Anja HaltnerValue & Evidence, EVERSANA™, New York, NY, USA.ORCID 0000-0002-9829-7791
Jonathan NazariGlobal Value and Evidence, Oncology, Pfizer, Inc., New York, NY, USA.ORCID 0000-0002-4758-7588
Alexander NiyazovGlobal Value and Evidence, Oncology, Pfizer, Inc., New York, NY, USA.
Imtiaz A SamjooValue & Evidence, EVERSANA™, Burlington, ON, Canada.ORCID 0000-0003-1415-8055

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe absence of direct comparisons between talazoparib plus enzalutamide (TALA+ENZA) and current standard of care hinders evaluating their relative efficacy for first-line (1 L) metastatic castration resistant prostate cancer (mCRPC). This study aimed to compare TALA+ENZA (TALAPRO-2) to abiraterone acetate plus prednisone (AAP) (COU-AA-302) and docetaxel (TAX 327) using a matching-adjusted indirect treatment comparison (MAIC).

methodsA systematic literature review using the Ovid® interface was performed to identify relevant evidence. Patient-level data from TALAPRO-2 and published data from COU-AA-302 and TAX 327 were used to match populations on clinically relevant confounders. The MAICs were conducted for radiographic progression-free survival (rPFS), overall survival (OS), objective response rate (ORR), along with additional efficacy outcomes.

resultsIn all-comers, TALA+ENZA statistically significantly prolonged rPFS (HR: 0.256; 95% confidence interval [CI]: 0.183, 0.359;

conclusionsThese results suggest TALA+ENZA improves clinical outcomes relative to AAP and docetaxel in the 1 L mCRPC all-comers population.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsProstatic Neoplasms, Castration-ResistantAbiraterone AcetateBenzamidesDocetaxelHumansMaleNitrilesPhenylthiohydantoinProgression-Free SurvivalTreatment OutcomeAbiraterone AcetateBenzamidesDocetaxelenzalutamideNitrilesPhenylthiohydantoinmatching-adjusted indirect comparisonMetastatic castration-resistant prostate cancerPARP inhibitorsystematic literature reviewtalazoparib

Identifiers

PMID40045559
PMCPMC11988211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.